KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Treasury Shares (2020 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Treasury Shares for 6 consecutive years, with $396693.0 as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 4.9% to $396693.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $396693.0, a 4.9% increase, with the full-year FY2025 number at $396693.0, up 4.9% from a year prior.
  • Treasury Shares was $396693.0 for Q4 2025 at Supernus Pharmaceuticals, down from $419216.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $419216.0 in Q2 2025 to a low of $20000.0 in Q4 2023.
  • A 5-year average of $210672.7 and a median of $151730.0 in 2023 define the central range for Treasury Shares.
  • Biggest YoY gain for Treasury Shares was 1790.82% in 2024; the steepest drop was 93.36% in 2024.
  • Supernus Pharmaceuticals' Treasury Shares stood at $21110.0 in 2021, then surged by 525.11% to $131960.0 in 2022, then crashed by 84.84% to $20000.0 in 2023, then soared by 1790.82% to $378165.0 in 2024, then rose by 4.9% to $396693.0 in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Treasury Shares are $396693.0 (Q4 2025), $419216.0 (Q2 2025), and $407867.0 (Q1 2025).